TTOO - T2 Biosystems, Inc.
| Previous Close | 0.8000 |
| Open | 0.8000 |
| Bid | 0.8476 x 1100 |
| Ask | 0.8500 x 1100 |
| Day's Range | 0.7901 - 0.8750 |
| 52 Week Range | 0.5200 - 7.7000 |
| Volume | 349,713 |
| Avg. Volume | 1,500,450 |
| Market Cap | 37.664M |
| Beta (3Y Monthly) | 1.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2840 |
| Earnings Date | Feb 12, 2018 - Feb 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.13 |
- GlobeNewswire
T2 Biosystems Expands Access to its Innovative Rapid Diagnostic Technologies to Australia, Fiji and New Zealand
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it entered into an exclusive distribution agreement that allows the Company to introduce its rapid diagnostic technologies, including the T2Bacteria® and T2Candida® Panels, and enter into new markets in Australia, Fiji, and New Zealand. “This latest geographic expansion represents another step forward in our fight against sepsis and the negative consequences associated with it, including high mortality rates, rising hospital expenses, and growing antimicrobial resistance,” said John McDonough, chairman and chief executive officer at T2 Biosystems. “Through rapid detection of sepsis-causing pathogens in the bloodstream, the T2Bacteria Panel and T2Candida Panel have the potential to help clinicians make earlier and better informed therapy decisions that enable changes in patient outcomes.
- GlobeNewswire
T2 Biosystems Reports Granting of Inducement Awards
The inducement awards consist of options to purchase 53,000 shares of T2 Biosystems common stock and have a ten-year term. The exercise price of the options is $0.58, which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on August 1, 2019. T2 Biosystems, a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before.
- GlobeNewswire
T2Bacteria Panel is the First and Only In-Vitro Diagnostic Test to Receive Approval for a New Technology Add-on Payment by CMS
T2 Biosystems, Inc. (TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that the United States Centers for Medicare & Medicaid Services (CMS) granted approval for a New Technology Add-on Payment (NTAP) for the T2Bacteria® Panel for FY 2020. “By approving NTAP for the T2Bacteria Panel, CMS has confirmed that the T2Bacteria Panel represents a substantial clinical improvement over existing technologies,” said John McDonough, chairman and chief executive officer at T2 Biosystems.
- Thomson Reuters StreetEvents
Edited Transcript of TTOO earnings conference call or presentation 30-Jul-19 8:30pm GMT
Q2 2019 T2 Biosystems Inc Earnings Call
- TheStreet.com
Swinging for the Small-Cap Biotech Fences Requires Accepting Strikeouts
Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.
- American City Business Journals
Lexington diagnostics maker T2 Biosystems' stock plummets on CEO departure, low earnings
Lexington sepsis and lyme disease diagnostics maker T2 Biosystems will soon have a new CEO to lead it through its ongoing financial struggles.
- Benzinga
The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals ...
- Zacks
T2 Biosystems (TTOO) Reports Q2 Loss, Misses Revenue Estimates
T2 Biosystems (TTOO) delivered earnings and revenue surprises of -9.38% and -10.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
T2 Biosystems Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Announces Two Financing Agreements to Potentially Provide up to $60 Million of Additional Capital; Reducing Cash Burn by 30% by Q4 2019 Achieved $1.8 Million in Total Revenue.
- ACCESSWIRE
T2 Biosystems, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July, 30 2019 / T2 Biosystems, Inc. (NASDAQ: TTOO ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July, 30 2019 at 4:30 PM Eastern ...
- GlobeNewswire
T2 Biosystems to Present at the Canaccord Genuity Growth Conference
LEXINGTON, Mass., July 30, 2019 -- T2 Biosystems, Inc. (the “Company”) (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic.
- GlobeNewswire
T2 Biosystems Expands Global Access to its Innovative Rapid Diagnostic Technologies
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it entered into exclusive distribution agreements with five new distribution partners in the first half of 2019. This allowed the Company to introduce its rapid diagnostic technologies, including the T2Bacteria® and T2Candida® Panels, and enter into new markets in Estonia, Greece, Ireland, Saudi Arabia and South Africa.
- GlobeNewswire
T2 Biosystems Announces 2019 Second Quarter Financial and Operational Results Release and Conference Call Date
LEXINGTON, Mass., July 24, 2019 -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs.
- Simply Wall St.
Before You Buy T2 Biosystems, Inc. (NASDAQ:TTOO), Consider Its Volatility
Anyone researching T2 Biosystems, Inc. (NASDAQ:TTOO) might want to consider the historical volatility of the share...
- GlobeNewswire
T2 Biosystems Named One of the Fastest-Growing Companies in Massachusetts
This recognition comes on the heels of several recent updates announced by the Company regarding expanding capabilities of its portfolio of groundbreaking rapid diagnostics and technology. One of the key products that was highlighted, the T2Bacteria® Panel, is the first and only FDA-cleared test to identify sepsis-causing bacterial pathogens directly from whole blood in 3 to 5 hours without the need to wait for blood culture, allowing patients to be placed on targeted antibiotic therapy faster. The T2Bacteria Panel is one of several panels that are approved or in development that are run on the Company’s T2Dx® Instrument, which is powered by miniaturized magnetic resonance (T2MR®) technology.
- GlobeNewswire
T2 Biosystems Introduces New Clinical Data and Updates Regarding Expanding Capabilities of its Rapid Diagnostic Technology at ASM Microbe 2019
T2 Biosystems, Inc. (TTOO), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, will share multiple updates regarding the clinical utility of its expanding portfolio of groundbreaking rapid diagnostics and technology during ASM Microbe 2019 in San Francisco, CA from June 19 to 24. “The T2Bacteria® and T2Candida® panels are the first-and-only FDA cleared tests that can provide direct-from-blood, rapid diagnostics for patients suspected of blood stream infection or sepsis.
- GlobeNewswire
T2 Biosystems Highlights Current and Future Opportunities for its Breakthrough Rapid Diagnostic Technology for Biothreat Pathogen Detection
T2 Biosystems, Inc. (TTOO), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that the Company will present new data regarding the potential of its technology to be used for the rapid detection of biothreat pathogens during the Fifth Annual Biodefense World Summit 2019, taking place June 17 – 19 in Bethesda, MD. The presentation, A Rapid, Direct-from-Blood Diagnostic to Address Infections from Multidrug Resistant Organisms (MDROs), will take place on Monday, June 17 at 12:00 pm and will feature Tom Lowery, PhD, chief scientific officer, T2 Biosystems.
- GlobeNewswire
T2 Biosystems to Highlight its Products and Technology at Upcoming Medical Meetings
LEXINGTON, Mass., June 12, 2019 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare,.
- Simply Wall St.
Do Institutions Own T2 Biosystems, Inc. (NASDAQ:TTOO) Shares?
If you want to know who really controls T2 Biosystems, Inc. (NASDAQ:TTOO), then you'll have to look at the makeup of...
- GlobeNewswire
New Studies Highlight Potential for T2Bacteria and T2Candida Panels to Improve Outcomes and be Cost-Effective for Sepsis Patients in the Medical Intensive Care Unit and Emergency Department
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today the publication of two independent, peer-reviewed studies highlighting the potential of the T2Bacteria and T2Candida Panels to improve outcomes and be cost-effective for a wide range of clinical scenarios. The most recent study, titled “Cost-effectiveness of molecular diagnostic assays for the therapy of severe sepsis and septic shock in the emergency department,” was published in the online journal PLOS ONE.
- GlobeNewswire
T2 Biosystems to Participate in Singular Research Spring Select Web Call
LEXINGTON, Mass., May 24, 2019 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare,.
- GlobeNewswire
Robust Clinical Data and Positive Customer Experience with T2Bacteria and T2Candida Panels Highlighted at Recent Medical Meetings
T2 Biosystems, Inc. (TTOO), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, highlighted the latest clinical data and customer case studies for the T2Bacteria® and T2Candida® Panels that were presented at recent medical meetings. In April, case studies of patients tested with the T2Bacteria Panel and T2Resistance™ Panel were presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam in an Integrated Symposium by Dr. Giulia De Angelis from the Institute of Microbiology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli in Rome, Italy.
- GlobeNewswire
Publication in Annals of Internal Medicine® Reveals T2Bacteria® Panel as the First Direct-from-Blood, Non-Culture Test that Rapidly Diagnoses Bacterial Bloodstream Infections
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that results from a pivotal trial were published online in the Annals of Internal Medicine® journal. A Diagnostic Accuracy Study," demonstrated decisive evidence for the first direct-from-blood, non-culture test cleared by the U.S. Food and Drug Administration (FDA) for the diagnosis of bloodstream infections by multiple bacteria. The T2Bacteria® Panel received FDA clearance in May 2018 and is the first and only FDA-cleared test to identify sepsis-causing bacteria directly from whole blood without the wait for blood culture, which currently takes 1 to 5 or more days and is the current standard of care for diagnosing bloodstream infections (BSIs).
